Literature DB >> 30197221

Juvenile Ocular Myasthenia Gravis: Presentation and Outcome of a Large Cohort.

Kavin Vanikieti1, Kasamon Lowwongngam1, Tanyatuth Padungkiatsagul2, Anannit Visudtibhan3, Anuchit Poonyathalang1.   

Abstract

BACKGROUND: Isolated ocular myasthenia gravis (MG) is sparingly common in children relative to adults, ranging from 71% to 93% of all children with MG.
PURPOSE: We aimed to characterize the ocular manifestations and outcomes in children with isolated ocular MG.
METHODS: Medical records of consecutive 62 subjects less than 15 years of age with ocular MG, were retrospectively reviewed. Demographic data, presenting ocular features, types and variabilities of duction limitation, MG confirmatory tests, types of and responses to treatment, and generalized MG conversion were reviewed.
RESULTS: Mean age at onset and follow-up time were 49 months (range, one to 173 months) and 95 months (range, six to 226 months), respectively. Female-to-male ratio was 1.5:1. Initially, ptosis was found in 60 subjects (96.8%), while duction limitation was observed in 28 subjects (45.2%). Total ophthalmoparesis was the most common type of duction limitation. Variability of duction limitation was found in 68% of subjects during the follow-up. Pyridostigmine alone was the most common medication used (48.4%); ptosis was more responsive to therapy than duction limitation. Conversion to generalized MG occurred in 19.4% of subjects, with a mean interval to conversion of nine months after symptom onset. Most conversions (91.7%) occurred in the first two years.
CONCLUSIONS: Ptosis was more responsive to treatment than duction limitation. Thus other treatment modalities, as well as strabismic amblyopia screening, should be considered in children with prolonged duction limitation that is refractory to medication. In contrast with adults, a much lower proportion of children converted to generalized MG. This may explain the higher prevalence of isolated ocular MG among the juvenile population.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Childhood; Juvenile; Ocular myasthenia gravis; Pediatric

Mesh:

Substances:

Year:  2018        PMID: 30197221     DOI: 10.1016/j.pediatrneurol.2018.06.007

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

Review 1.  The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review.

Authors:  Jeannine M Heckmann; Tarin A Europa; Aayesha J Soni; Melissa Nel
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

2.  Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort.

Authors:  Lifen Yang; Yulin Tang; Fang He; Ciliu Zhang; Miriam Kessi; Jing Peng; Fei Yin
Journal:  Front Pediatr       Date:  2022-09-29       Impact factor: 3.569

3.  Local use of dexamethasone in the treatment of ocular myasthenia gravis.

Authors:  Minghua Shi; Yingjia Ye; Junping Zhou; Aijiao Qin; Jing Cheng; Hongxing Ren
Journal:  BMC Ophthalmol       Date:  2020-10-28       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.